title: Development of hepatocellular carcinoma following treatment with 6-mercaptopurine for ulcerative colitis: investigation of chromosomal aberration by comparative genomic hybridization.
abstract: In a 64-year-old man who had been treated with prednisolone (PSL) and 6-mercaptopurine (6MP) for a long period, for ulcerative colitis (UC), hepatocellular carcinoma (HCC) was detected incidentally. The UC was in remission with these medications. After he had been taking these medications for about 8 years, HCC was detected by computed tomography (CT), done for the evaluation of an other disease. Blood chemistry examination results were normal, except that the protein induced by vitamin K antagonist (PIVKA)-II level was 7940 AU/ml. We performed resection of liver segment V. With comparative genomic hybridization, chromosomal aberrations were recognized; these were gains of 1q, 3ptel-21, 8p12, and 22q11.23-22q13.1. Generally, HCC is associated with hepatitis virus infection in most cases, but in this patient, the HCC was not related to hepatitis C virus (HCV) or HBV. It is presumed that this case was related to the immunosuppressive therapy for UC and was associated with the gains of 1q, 3p, and 8p.
authors.affiliation: Second Department of Surgery, Showa University School of Medicine, 1-5-8 Hatanodai, Tokyo 146-8666, Japan. knakao@med.showa-u.ac.jp
authors.forename: Kentaro
authors.initials: K
authors.lastname: Nakao
authors.forename: Akira
authors.initials: A
authors.lastname: Tsunoda
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Shimizu
authors.forename: Koji
authors.initials: K
authors.lastname: Takenaka
authors.forename: Koji
authors.initials: K
authors.lastname: Morohara
authors.forename: Naoto
authors.initials: N
authors.lastname: Suzuki
authors.forename: Katsuo
authors.initials: K
authors.lastname: Yamazaki
authors.forename: Takeshi
authors.initials: T
authors.lastname: Aoki
authors.forename: Mitsunori
authors.initials: M
authors.lastname: Hoshino
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Kusano
authors.forename: Eri
authors.initials: E
authors.lastname: Kitadai
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Kurihara
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Takeuchi
authors.forename: Michio
authors.initials: M
authors.lastname: Imawari
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000235:genetics; D002869:Chromosome Aberrations; D002878:Chromosomes, Human, Pair 1 / Q000235:genetics; D002892:Chromosomes, Human, Pair 22 / Q000235:genetics; D002893:Chromosomes, Human, Pair 3 / Q000235:genetics; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000276:immunology; D005784:Gene Amplification; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D008113:Liver Neoplasms / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000235:genetics; D008297:Male; D015122:Mercaptopurine / Q000009:adverse effects*; D008875:Middle Aged; D009693:Nucleic Acid Hybridization; D014057:Tomography, X-Ray Computed
chemical_list: D007166:Immunosuppressive Agents; D015122:Mercaptopurine